These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23727946)

  • 1. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction.
    Nakamura Y; Suzuki S; Saitoh S; Takeishi Y
    Biol Pharm Bull; 2013; 36(8):1326-31. PubMed ID: 23727946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and tolerability of azilsartan in mice with left ventricular pressure overload or acute myocardial infarction.
    Quinn Baumann P; Zaman AK; McElroy-Yaggy K; Sobel BE
    J Cardiovasc Pharmacol; 2013 May; 61(5):437-43. PubMed ID: 23429590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats.
    Zhang RY; Wang LF; Zhang L; Meng XN; Li SJ; Wang WR
    Chin Med J (Engl); 2006 Apr; 119(8):649-55. PubMed ID: 16635409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction.
    Matsusaka H; Kinugawa S; Ide T; Matsushima S; Shiomi T; Kubota T; Sunagawa K; Tsutsui H
    J Cardiovasc Pharmacol; 2006 Sep; 48(3):95-102. PubMed ID: 17031262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma.
    Maejima Y; Okada H; Haraguchi G; Onai Y; Kosuge H; Suzuki J; Isobe M
    Lab Invest; 2011 Jun; 91(6):932-44. PubMed ID: 21403641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling.
    Kohno T; Anzai T; Naito K; Sugano Y; Maekawa Y; Takahashi T; Yoshikawa T; Ogawa S
    Circ J; 2008 Oct; 72(10):1685-92. PubMed ID: 18753699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.
    Matsumoto R; Yoshiyama M; Omura T; Kim S; Nakamura Y; Izumi Y; Akioka K; Iwao H; Takeuchi K; Yoshikawa J
    Circ J; 2004 Apr; 68(4):376-82. PubMed ID: 15056838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.
    Kassiri Z; Zhong J; Guo D; Basu R; Wang X; Liu PP; Scholey JW; Penninger JM; Oudit GY
    Circ Heart Fail; 2009 Sep; 2(5):446-55. PubMed ID: 19808375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction.
    Kusuyama T; Yoshiyama M; Omura T; Nishiya D; Enomoto S; Matsumoto R; Izumi Y; Akioka K; Takeuchi K; Iwao H; Yoshikawa J
    J Pharmacol Sci; 2005 Jul; 98(3):283-9. PubMed ID: 15997171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azilsartan attenuates cardiac damage caused by high salt intake through the downregulation of the cardiac (pro)renin receptor and its downstream signals in spontaneously hypertensive rats.
    Komaki H; Iwasa M; Hayakawa Y; Okamoto C; Minatoguchi S; Yamada Y; Kanamori H; Kawasaki M; Nishigaki K; Minatoguchi S
    Hypertens Res; 2018 Nov; 41(11):886-896. PubMed ID: 30209283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure.
    Hoshi-Fukushima R; Nakamoto H; Imai H; Kanno Y; Ishida Y; Yamanouchi Y; Suzuki H
    Am J Nephrol; 2008; 28(3):413-23. PubMed ID: 18097133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
    van den Borne SW; Isobe S; Zandbergen HR; Li P; Petrov A; Wong ND; Fujimoto S; Fujimoto A; Lovhaug D; Smits JF; Daemen MJ; Blankesteijn WM; Reutelingsperger C; Zannad F; Narula N; Vannan MA; Pitt B; Hofstra L; Narula J
    JACC Cardiovasc Imaging; 2009 Feb; 2(2):187-98. PubMed ID: 19356555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction.
    Ellmers LJ; Scott NJ; Medicherla S; Pilbrow AP; Bridgman PG; Yandle TG; Richards AM; Protter AA; Cameron VA
    Endocrinology; 2008 Nov; 149(11):5828-34. PubMed ID: 18653707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice.
    Jehle AB; Xu Y; Dimaria JM; French BA; Epstein FH; Berr SS; Roy RJ; Kemp BA; Carey RM; Kramer CM
    J Cardiovasc Pharmacol; 2012 Apr; 59(4):363-8. PubMed ID: 22157261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction.
    Nakamura Y; Yoshiyama M; Omura T; Yoshida K; Izumi Y; Takeuchi K; Kim S; Iwao H; Yoshikawa J
    Cardiovasc Res; 2003 Jan; 57(1):48-54. PubMed ID: 12504813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
    Pourdjabbar A; Parker TG; Nguyen QT; Desjardins JF; Lapointe N; Tsoporis JN; Rouleau JL
    Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1997-2005. PubMed ID: 15539424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction.
    Maekawa Y; Anzai T; Yoshikawa T; Sugano Y; Mahara K; Kohno T; Takahashi T; Ogawa S
    J Am Coll Cardiol; 2004 Oct; 44(7):1510-20. PubMed ID: 15464336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
    Iwanami J; Mogi M; Tsukuda K; Wang XL; Nakaoka H; Ohshima K; Chisaka T; Bai HY; Kanno H; Min LJ; Horiuchi M
    Hypertens Res; 2014 Jul; 37(7):616-20. PubMed ID: 24599018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.